Tyra Biosciences (TYRA) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.
The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.
TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.
Shares of the company were down nearly 5% in recent trading.
Price: 15.18, Change: -0.79, Percent Change: -4.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。